Glutathione-depleting Liposome Adjuvant for Augmenting the Efficacy of a Glutathione Covalent Inhibitor Oridonin for Acute Myeloid Leukemia Therapy

Yi Liu,Xiaoning Wang,Hui Feng,Xinyan Li,Runyu Yang,Mengyao Zhang,Yue Du,Ruimin Liu,Minna Luo,Zhiyi Li,Bo Liu,Jincheng Wang,Wenjuan Wang,Feifei An,Fan Niu,Pengcheng He
DOI: https://doi.org/10.1186/s12951-024-02574-6
IF: 10.2
2024-05-31
Journal of Nanobiotechnology
Abstract:Discrepancies in the utilization of reactive oxygen species (ROS) between cancer cells and their normal counterparts constitute a pivotal juncture for the precise treatment of cancer, delineating a noteworthy trajectory in the field of targeted therapies. This phenomenon is particularly conspicuous in the domain of nano-drug precision treatment. Despite substantial strides in employing nanoparticles to disrupt ROS for cancer therapy, current strategies continue to grapple with challenges pertaining to efficacy and specificity. One of the primary hurdles lies in the elevated levels of intracellular glutathione (GSH). Presently, predominant methods to mitigate intracellular GSH involve inhibiting its synthesis or promoting GSH efflux. However, a conspicuous gap remains in the absence of a strategy capable of directly and efficiently clearing GSH.
biotechnology & applied microbiology,nanoscience & nanotechnology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to effectively remove glutathione (GSH) in cancer cells during the treatment of acute myeloid leukemia (AML), thereby enhancing the killing effect of drugs on cancer cells. Specifically, the paper focuses on the following aspects: 1. **Improving drug targeting**: By designing a nano - drug delivery system that can specifically target AML cells, increase the accumulation of drugs in cancer cells and reduce the impact on normal cells. 2. **Direct removal of GSH**: Current methods mainly focus on inhibiting the synthesis of GSH or promoting its efflux, but lack strategies for directly and efficiently removing GSH. The paper proposes a new method that directly removes GSH by using the covalent binding of oridonin and GSH and the auxiliary effect of maleimide liposomes. 3. **Enhancing drug potency**: By combining oridonin and maleimide liposomes, as well as TLR2 - targeting peptides, enhance the killing effect of drugs on AML cells while reducing the toxic and side effects of drugs. ### Main content of the paper #### Background - **ROS and cancer**: There are differences between cancer cells and normal cells in the use of reactive oxygen species (ROS), which provides an important approach for the precise treatment of cancer. This phenomenon is particularly significant in the field of nano - drug precision treatment. - **Existing challenges**: Although significant progress has been made in using nanoparticles to destroy ROS for cancer treatment, challenges still remain in terms of efficacy and specificity. One of the main obstacles is the high level of glutathione (GSH) in cells. - **The role of GSH**: GSH is a key component of the cell antioxidant system. Cancer cells rely on high GSH levels to clear excess ROS and detoxify foreign substances. Therefore, GSH has become a potential target for cancer treatment. #### Methods - **Mechanism of oridonin**: First, clarify the chemical mechanism by which oridonin interferes with ROS through covalent interaction with GSH. - **Application of maleimide liposomes**: By introducing maleimide liposomes, improve the water - solubility and pharmacokinetics of drugs and enhance their effect of destroying ROS. - **Combination of TLR2 - targeting peptides**: Utilize the reaction mechanism between maleimide and sulfhydryl groups to couple TLR2 - targeting peptides to the surface of liposomes, further improving the targeting and potency of drugs on AML cells. #### Results - **In vitro experiments**: The designed liposome complex can penetrate AML cells more quickly and specifically, and more effectively induce an increase in ROS and depletion of GSH, leading to apoptosis of AML cells. - **In vivo experiments**: In the AML mouse model, the designed liposome complex significantly prolongs the survival time of tumor - bearing mice and has a longer enrichment time in AML cells. In addition, no non - specific toxicity to normal cells and organs has been observed, confirming its safety. #### Conclusion - **Innovation**: The rationally designed nanocomplex provides a platform for enhancing ROS drugs and targeted delivery. By disrupting the redox balance, it provides a potential solution for AML treatment. ### Keywords - Oridonin - Peptide - based drug delivery - Glutathione inhibitor - ROS - AML treatment Through these studies, the paper provides a new strategy for AML treatment and is expected to achieve better curative effects in clinical applications.